Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

NCT05050500 is registered in ClinicalTrials.gov with Qingdao Central Hospital as lead sponsor.

NCT NCT05050500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction
Lead sponsor
Qingdao Central Hospital
Phase
Phase 4
Overall status
Completed
Start date
May 8, 2023
Completion date
December 30, 2024
Enrollment
143 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabete type 2, glucose intolerance, myocardial infarction